Evidence mapPaperPMID 39795101Full record

ReviewMolecules (Basel, Switzerland)2024

A Review on Current Aspects of Curcumin-Based Effects in Relation to Neurodegenerative, Neuroinflammatory and Cerebrovascular Diseases.

Claudia-Andreea Moldoveanu, Maria Tomoaia-Cotisel, Alexandra Sevastre-Berghian, Gheorghe Tomoaia, Aurora Mocanu, Csaba Pal-Racz, Vlad-Alexandru Toma, Ioana Roman, Madalina-Anca Ujica, Lucian-Cristian Pop

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Article
  7. Curcumin Between Pleiotropic Potential and Translational Constraints.International journal of molecular sciences · 2026
    Review
  8. Review
  9. Is Obesity a Modifiable Risk Factor in Multiple Sclerosis? Mechanistic Insights into Neuroinflammation and Oxidative Damage.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026
    Review
  10. Pharmacological Insights and Technological Innovations inPharmaceuticals (Basel, Switzerland) · 2026
    Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Claudia-Andreea MoldoveanuDepartment of Molecular Biology and Biotechnology, Babeș-Bolyai University, Clinicilor St., RO-400371 Cluj-Napoca, Romania.
Maria Tomoaia-CotiselResearch Center of Excellence in Physical Chemistry, Faculty of Chemistry and Chemical Engineering, "Babes-Bolyai University", 11 Arany Janos St., RO-400028 Cluj-Napoca, Romania.
Alexandra Sevastre-BerghianDepartment of Physiology, Faculty of Medicine, "Iuliu Hațieganu" University of Medicine and Pharmacy, 1 Clinicilor St., RO-400006 Cluj-Napoca, Romania.
Gheorghe TomoaiaAcademy of Romanian Scientists, 3 Ilfov St., RO-050044 Bucharest, Romania.
Aurora MocanuResearch Center of Excellence in Physical Chemistry, Faculty of Chemistry and Chemical Engineering, "Babes-Bolyai University", 11 Arany Janos St., RO-400028 Cluj-Napoca, Romania.
Csaba Pal-RaczResearch Center of Excellence in Physical Chemistry, Faculty of Chemistry and Chemical Engineering, "Babes-Bolyai University", 11 Arany Janos St., RO-400028 Cluj-Napoca, Romania.
Vlad-Alexandru TomaDepartment of Molecular Biology and Biotechnology, Babeș-Bolyai University, Clinicilor St., RO-400371 Cluj-Napoca, Romania.ORCID 0000-0002-1141-2559
Ioana RomanDepartment of Experimental Biology and Biochemistry, Institute of Biological Research from Cluj-Napoca, a Branch of NIRDBS Bucharest, 48 Republicii St., RO-400015 Cluj-Napoca, Romania.ORCID 0000-0001-8002-8035
Madalina-Anca UjicaResearch Center of Excellence in Physical Chemistry, Faculty of Chemistry and Chemical Engineering, "Babes-Bolyai University", 11 Arany Janos St., RO-400028 Cluj-Napoca, Romania.
Lucian-Cristian PopResearch Center of Excellence in Physical Chemistry, Faculty of Chemistry and Chemical Engineering, "Babes-Bolyai University", 11 Arany Janos St., RO-400028 Cluj-Napoca, Romania.ORCID 0000-0002-1778-9226

Funding

Ministerul Cercetării și Inovării CNCS/CCCDI-UEFISCDI, PN-III-P4-ID-PCE-2020-1910 no 186
6 · The paper itself

Abstract

Curcumin is among the most well-studied natural substances, known for its biological actions within the central nervous system, its antioxidant and anti-inflammatory properties, and human health benefits. However, challenges persist in effectively utilising curcumin, addressing its metabolism and passage through the blood-brain barrier (BBB) in therapies targeting cerebrovascular diseases. Current challenges in curcumin's applications revolve around its effects within neoplastic tissues alongside the development of intelligent formulations to enhance its bioavailability. Formulations have been discovered including curcumin's complexes with brain-derived phospholipids and proteins, or its liposomal encapsulation. These novel strategies aim to improve curcumin's bioavailability and stability, and its capability to cross the BBB, thereby potentially enhancing its efficacy in treating cerebrovascular diseases. In summary, this review provides a comprehensive overview of molecular pathways involved in interactions of curcumin and its metabolites, and brain vascular homeostasis. This review explores cellular and molecular current aspects, of curcumin-based effects with an emphasis on curcumin's metabolism and its impact on pathological conditions, such as neurodegenerative diseases, schizophrenia, and cerebral angiopathy. It also highlights the limitations posed by curcumin's poor bioavailability and discusses ongoing efforts to surpass these impediments to harness the full therapeutic potential of curcumin in neurological disorders.

Indexed as

Cerebrovascular DisordersCurcuminNeurodegenerative DiseasesNeuroinflammatory DiseasesAnimalsAnti-Inflammatory AgentsBiological AvailabilityBlood-Brain BarrierHumansAnti-Inflammatory AgentsCurcuminbenefits and limiting effectsbioavailabilitycerebrovascular diseasescurcuminformulations blood–brain barrier

Identifiers

PMID39795101
PMCPMC11722367

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.